Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

GALVANO, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.487
EU - Europa 4.556
AS - Asia 3.911
Continente sconosciuto - Info sul continente non disponibili 716
SA - Sud America 707
AF - Africa 141
OC - Oceania 18
Totale 19.536
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.253
SG - Singapore 1.565
RU - Federazione Russa 1.411
IT - Italia 1.139
CN - Cina 850
BR - Brasile 562
DE - Germania 485
VN - Vietnam 412
HK - Hong Kong 354
FI - Finlandia 298
PL - Polonia 267
GB - Regno Unito 232
FR - Francia 224
JP - Giappone 148
CA - Canada 127
BD - Bangladesh 105
IN - India 105
IE - Irlanda 89
SE - Svezia 82
KR - Corea 77
NL - Olanda 76
IQ - Iraq 52
MX - Messico 50
AR - Argentina 45
RO - Romania 44
TR - Turchia 43
ES - Italia 39
UA - Ucraina 37
ZA - Sudafrica 34
AT - Austria 28
BE - Belgio 26
VE - Venezuela 24
EC - Ecuador 23
UZ - Uzbekistan 23
IR - Iran 21
MY - Malesia 21
EG - Egitto 20
ID - Indonesia 18
MA - Marocco 18
AU - Australia 17
KE - Kenya 17
CI - Costa d'Avorio 16
SA - Arabia Saudita 16
CH - Svizzera 14
JM - Giamaica 14
PK - Pakistan 14
CL - Cile 12
PH - Filippine 12
CO - Colombia 11
LT - Lituania 11
NP - Nepal 11
PT - Portogallo 11
TN - Tunisia 10
PY - Paraguay 9
UY - Uruguay 9
AE - Emirati Arabi Uniti 8
CR - Costa Rica 8
CZ - Repubblica Ceca 7
PE - Perù 7
AM - Armenia 6
AZ - Azerbaigian 6
BG - Bulgaria 6
DZ - Algeria 5
GT - Guatemala 5
KZ - Kazakistan 5
LB - Libano 5
RS - Serbia 5
TT - Trinidad e Tobago 5
TW - Taiwan 5
AL - Albania 4
BO - Bolivia 4
DO - Repubblica Dominicana 4
GH - Ghana 4
HN - Honduras 4
PA - Panama 4
PS - Palestinian Territory 4
SV - El Salvador 4
EE - Estonia 3
GR - Grecia 3
HU - Ungheria 3
IL - Israele 3
JO - Giordania 3
KG - Kirghizistan 3
LV - Lettonia 3
NG - Nigeria 3
NI - Nicaragua 3
OM - Oman 3
AO - Angola 2
BB - Barbados 2
BY - Bielorussia 2
LY - Libia 2
MD - Moldavia 2
MK - Macedonia 2
MM - Myanmar 2
SN - Senegal 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BM - Bermuda 1
Totale 18.799
Salva come PNG Salva come JPEG
Città #
Ashburn 1.211
Fairfield 975
Singapore 950
San Jose 597
Chandler 487
Houston 454
Seattle 417
Woodbridge 405
Wilmington 349
Cambridge 336
Hong Kong 336
Palermo 297
Moscow 284
Ann Arbor 261
Zgierz 217
Helsinki 186
Council Bluffs 176
Beijing 165
Los Angeles 161
New York 159
Rome 158
Dallas 148
Ho Chi Minh City 137
The Dalles 136
Tokyo 136
Lauterbourg 110
Santa Clara 107
Medford 102
Munich 102
Hefei 100
Hanoi 98
Des Moines 87
Boardman 85
Dublin 85
Altamura 77
Chicago 73
Princeton 65
Buffalo 63
Frankfurt am Main 62
Lawrence 60
São Paulo 59
Ludwigshafen am Rhein 54
London 53
San Diego 53
Milan 51
Nanjing 47
Warsaw 45
Orem 39
Seoul 38
Toronto 35
Denver 33
Lappeenranta 32
Schiffdorf 32
Atlanta 31
Bremen 31
Montreal 31
Dearborn 30
Phoenix 30
Brooklyn 29
Nuremberg 29
Kitzingen 27
Panama City 25
Brussels 23
Stockholm 23
Johannesburg 22
Chennai 21
Redondo Beach 21
Mexico City 20
Amsterdam 19
Falls Church 19
Shanghai 19
Tashkent 19
Baghdad 18
Salt Lake City 18
Shenyang 18
Boston 17
Haiphong 17
Redwood City 17
Abidjan 16
Da Nang 16
Kumar 16
Cairo 15
Manchester 15
Nanchang 15
Tianjin 15
Guangzhou 14
Hebei 14
Volla 14
Belo Horizonte 13
Memphis 13
Poplar 13
Tampa 13
Curitiba 12
Erbil 12
Izmir 12
Jinan 12
Nairobi 12
Rio de Janeiro 12
Berlin 11
Bexley 11
Totale 11.855
Salva come PNG Salva come JPEG
Nome #
Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: Systematic review and meta-analysis of randomized controlled trials 480
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 357
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 351
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 351
Dietary restriction: could it be considered as speed bump on tumor progression road? 329
Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin 329
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 329
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 320
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 314
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 309
Cardiotoxic Effects of Anti-VEGFR Tyrosine Kinase Inhibitors 306
Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study 287
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 283
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway 277
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis 271
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 265
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 261
Nintedanib in NSCLC: Evidence to date and place in therapy 261
Monoclonal antibodies in gastrointestinal cancers 252
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 250
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 248
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma 238
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 230
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 215
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) 211
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 208
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 206
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 204
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 204
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 202
Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity and safety and phase II study 195
2020 Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 194
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer 190
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy 190
An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesistargeting TKI-based therapy 190
Combined treatment with fulvestrant plus capecitabine in elderly advanced breast cancer (EABC): Three-year evaluation of efficacy and safety 188
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 185
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 182
COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients? 181
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? 180
Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin 178
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) 178
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study 174
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—A trial-level meta-analysis in PD-L1 selected subgroups 172
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 168
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement 167
Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma 164
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 163
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay 162
Dose-finding study of oxaliplatin associated to capecitabinebased preoperative chemoradiotherapy in locally advanced rectal cancer 160
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 159
The emerging therapeutic landscape of alk inhibitors in non-small cell lung cancer 158
The use of pegylated liposomal doxorubicin (PLD) in association with weekly paclitaxel as second line therapy in metastatic bladder carcinoma: final results 157
Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family” 156
Effects of the number of removed lymph nodes on survival outcome in patients with sentinel node-negative breast cancer 152
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab 150
Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer 150
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal 149
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study. 148
Applications of Platelet Concentrates (PCs) in Regenerative Onco-Urology: A Systematic Review of Literature 148
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study 147
Impact of BMI on Preoperative Axillary Ultrasound Assessment in Patients With Early Breast Cancer 147
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis 145
Liquid biopsy in colorectal carcinoma: the search for potential prognostic and predictive biomarkers 145
Second medical opinion in oncological setting 145
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials 144
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible 143
Ramucirumab and its use in gastric cancer treatment 142
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis 142
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? 141
Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients 140
The treatment of medication-related osteonecrosis of the jaw (Mronj): A systematic review with a pooled analysis of only surgery versus combined protocols 140
Molecular tumor board 139
Accuracy evaluation of orthodontic movements with aligners: a prospective observational study. 137
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials 133
The use of same in chemotherapy-induced liver injury 132
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses 132
Current clinically validated applications of liquid biopsy 130
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) 130
A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic 129
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 128
Scientific Communication and oncology – "The bridge between knowledge and patients" 124
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors 123
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors 123
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis 121
Indications for locoregional tumor therapies: CRC liver metastases 120
Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis 119
Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer 119
Extracellular Vesicles in Lung Cancer: Implementation in Diagnosis and Therapeutic Perspectives 116
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 116
Potential Applications of PRP-Enhanced Polybutylene Succinate Graft as Vascular Access for Chemotherapy in Oncological Patients: A Systematic Review 115
Anti-vibration Knob for the Motorcycle, Customizable on the Basis of the Driver’s Ergonomics 113
The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis 112
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials 112
Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis 110
The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors 109
Liquid biopsy and immunotherapy: is all that glitter gold? 109
Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and Healthcare 107
Early detection screening: myth or reality? 106
Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study 98
Totale 18.519
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.966
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.966
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.045 0 208 71 39 62 60 59 65 99 139 89 154
2022/20231.404 145 274 25 180 119 216 84 123 113 20 77 28
2023/2024859 28 96 74 71 59 130 108 80 30 31 14 138
2024/20252.751 73 181 173 186 122 203 338 239 151 317 340 428
2025/20268.339 682 302 574 780 930 1.186 1.174 895 620 499 321 376
2026/2027876 602 274 0 0 0 0 0 0 0 0 0 0
Totale 19.536